What this comparison tells you
Synthetic pentadecapeptide
BPC-157
EmergingSome studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation.- Evidence type
- Health results; use not approved
- Approval
- Still being studied; no FDA-approved BPC-157 product identified
- Approved products
- None identified in the United States.
- Sports status
- Prohibited
- Sources used
- 7 sources
- Last reviewed
- July 23, 2026
Cell and animal studies, plus small early studies in people, do not prove that BPC-157 heals injuries in people.
Synthetic thymosin beta-4 fragment
TB-500
InsufficientReliable studies in people are missing, too limited, or do not support the claim. This does not prove that the substance has no effect on the body.- Evidence type
- Cell, animal, or product tests
- Approval
- No FDA-approved TB-500 drug product
- Approved products
- None identified in the United States.
- Sports status
- Prohibited
- Sources used
- 3 sources
- Last reviewed
- August 1, 2026
A seven-amino-acid piece of thymosin beta-4 promoted for repair, without reliable human healing evidence and with major product and anti-doping limits.
How the evidence compares
These are separate questions, not one score. A peptide can be well understood in one area and uncertain in another.
Both peptide columns stay aligned. Read across each row to compare the same question. On smaller screens, each question shows both records together.
Each question shows both records together.
| Question checked | BPC-157Emerging | TB-500Insufficient |
|---|---|---|
| Health benefitsDid people's health improve? | BPC-157Limited Small uncontrolled pilots cannot establish a patient benefit. | TB-500Unclear FDA found no adequate human clinical outcome evidence for compounded TB-500 wound-healing use. |
| Body changes in peopleWhat body changes did studies in people measure? | BPC-157Limited Human exposure and pharmacokinetic characterization remain sparse. | TB-500Limited Fragment identity and laboratory findings do not establish a clinical benefit in people. |
| Known risksWhat do we know about risks in people? | BPC-157Limited The human safety dataset is too small for confident risk estimates. | TB-500Unclear Human exposure and product-specific safety information are inadequate. |
| Exact productDo we know what the product contains and how well it was made? | BPC-157Unclear No validated approved formulation; identity and purity vary outside formal research. | TB-500Unclear Nomenclature, salt form, purity, sterility, and fragment-versus-protein distinctions create major uncertainty. |
| Approval statusIs there a reviewed product for a specific use? | BPC-157 Still being studied; no FDA-approved BPC-157 product identified | TB-500 No FDA-approved TB-500 drug product |
Questions to ask before you compare
Use these questions to see whether the records match.
- 01
Did the research test cells, animals, or people?
- 02
Does the product name match what researchers tested?
- 03
Is there a controlled study showing healing in people?
- 04
What do current sport rules say, and what remains unknown?
What sources were used
The number of sources does not prove strength. Different sources answer different questions. A drug label, a trial, a cell study, and an agency review do not mean the same thing.
BPC-157
7 sources used
- Anti-doping1
- FDA review1
- Human pilot1
- Preclinical1
- Regulatory1
- Science review1
- Trial registry1
The preclinical literature contains positive signals in cell and animal models, including tendon-healing models. Small human pilot work and registered clinical research now exist, but do not establish a clinical effect in people. FDA's July 2026 PCAC briefing evaluated BPC-157-related bulk substances for a nominated ulcerative-colitis use and documented evidence and safety gaps. That advisory-stage record supports scrutiny; it is not a final FDA determination.
The available evidence still does not establish that BPC-157 safely heals sports injuries or other conditions in people. Early, uncontrolled, or registered research is not the same as a replicated patient benefit, and a trial listing is not a positive result.
TB-500
3 sources used
- Anti-doping1
- FDA review1
- Reference1
FDA has published a detailed 2026 briefing on TB-500's identity, characterization, proposed wound-healing use, and evidence gaps. WADA explicitly names TB-500 on the 2026 Prohibited List.
Reliable controlled studies in people do not establish faster tendon, muscle, or wound healing from TB-500. Safety, purity, sterility, long-term effects, and equivalence of marketed material remain uncertain.
Fact checks for each peptide
Each result applies only to the statement shown. Open its record to see the version and sources.
BPC-157
“BPC-157 improves tendon healing in preclinical models.”
Cell and rat tendon studies report positive healing signals. The scope matters: these results support biological plausibility, not a proven human treatment.
- Evidence used
- Cell, animal, or other lab research
- What this result covers
- Cell and animal tendon models only; not clinical healing outcomes in people.
“BPC-157 heals tendons and muscles in people.”
Early human work is too small and limited to establish efficacy. Reliable, replicated human outcome evidence is still needed.
- Evidence used
- No reliable studies showing this health result in people
- What this result covers
- Human tendon and muscle-healing claims; existing pilots and a trial registration do not establish benefit.
“Athletes can use it because it is not a steroid.”
The 2026 WADA Prohibited List places BPC-157 in S0 non-approved substances, which is prohibited at all times for covered athletes. Whether it is a steroid is irrelevant to that status.
- Evidence used
- Official record or product label
- What this result covers
- Athletes subject to the current WADA Code and their applicable governing-body rules.
TB-500
“TB-500 is the same thing as thymosin beta-4.”
FDA describes TB-500 as a seven-amino-acid fragment of the much larger thymosin beta-4 molecule.
- Evidence used
- Official record or product label
- What this result covers
- Chemical identity, not a claim about all possible biological activity.
“TB-500 accelerates tendon and muscle healing in people.”
The FDA evidence review did not identify adequate human outcome evidence for wound-healing use.
- Evidence used
- No reliable studies showing this health result in people
- What this result covers
- Clinical tendon, muscle, and wound-healing outcomes in people.
“TB-500 is allowed in tested sport.”
TB-500 is named on the current WADA Prohibited List.
- Evidence used
- Official record or product label
- What this result covers
- Sport governed by the World Anti-Doping Code.
Products with the same ingredient can differ
Evidence applies to the exact product used in a study. Check the peptide's amino-acid order, ingredients and form, how it enters the body, and where it came from. A shared ingredient name does not prove that another vial has the same benefits or risks.
BPC-157
15 amino acids · investigational
A peptide sequence, a nominated bulk substance, a clinical-study product, and a consumer vial are separate evidence objects. Identity and product quality cannot be assumed from the name.
No FDA product label was found for this molecule in the sources reviewed.
- No FDA-approved indication
TB-500
7 amino acids · N-terminal acetylated fragment
TB-500 is not the same as the full thymosin beta-4 molecule. FDA identifies TB-500 as a seven-amino-acid fragment, not as interchangeable with full-length thymosin beta-4. Internet naming and certificates do not establish product identity or clinical equivalence.
No FDA product label was found for this molecule in the sources reviewed.
- No FDA-approved indication
Sports rules and safety limits
These statuses do not give personal clearance to compete.
BPC-157
BPC-157 is listed under WADA's S0 non-approved substances category and is prohibited at all times for covered athletes.
Reviewed Read the governing record ↗The site will not provide self-injection, reconstitution, dosing, sourcing, or stack instructions. “Research use only” does not establish quality or make a product appropriate for human use.
TB-500
TB-500 is named as a prohibited thymosin-beta-4 derivative on the 2026 WADA Prohibited List and is prohibited at all times for covered athletes.
Reviewed Read the governing record ↗This is not an invitation to experiment. The guide provides no sourcing, reconstitution, injection, cycle, stack, or injury-treatment instructions.
Why people compare these two
People often market BPC-157 and TB-500 together for injury recovery. The reviewed records place them in the same family: recovery and repair claims. Both are sold with promises of faster tendon, muscle, and soft-tissue repair and with a “research use only” label.
Their records differ. BPC-157 is graded Emerging, with an evidence context of investigational human outcomes. TB-500 is graded Insufficient, with an evidence context of preclinical or formulation evidence. These classifications describe different evidence gaps.
The useful question is not which one works better. It is what evidence is missing for each one.
What was studied in cells, animals, and people
The BPC-157 record includes positive signals in cell and animal models, including tendon-healing models. It cites a rat and cell tendon-outgrowth study. The claim that BPC-157 improves tendon healing in preclinical models is graded Supported with scope: cell and animal tendon models only, not clinical healing outcomes in people.
The claim that BPC-157 heals tendons and muscles in people is graded Not established. Small human pilot work and registered clinical research now exist. The record cites a safety pilot of intravenous infusion in humans, a translational-barriers review, and an active hamstring-strain trial registration. Early, uncontrolled, or registered research is not the same as a replicated patient benefit, and a trial listing is not a positive result.
TB-500 has a different evidence gap. FDA's 2026 briefing on TB-500-related bulk substances evaluated identity, characterization, and a proposed wound-healing use. The record reports that FDA found no adequate human clinical outcome evidence for compounded TB-500 wound-healing use. Its human-outcomes axis is graded Unclear rather than Limited because the review did not find an adequate body of human evidence.
BPC-157 has animal evidence and more human research underway, but it lacks controlled human outcome data. TB-500 lacks controlled human outcome data and also lacks a settled identity.
TB-500's identity comes before its evidence
For TB-500, identity comes first. FDA describes it as a seven-amino-acid fragment—the N-terminal acetylated 17-23 fragment—of the larger thymosin beta-4 molecule. The claim that TB-500 is the same as thymosin beta-4 is graded Misleading.
Research on full-length thymosin beta-4 cannot automatically support a TB-500 fragment. A marketing page that uses that research for TB-500 has crossed an identity boundary the record does not support.
TB-500's product-certainty axis is graded Unclear because nomenclature, salt form, purity, sterility, and fragment-versus-protein differences create major uncertainty. Internet names and certificates do not establish product identity or clinical equivalence.
BPC-157's product-certainty axis is also graded Unclear, but for a narrower reason: no validated approved formulation anchors it, and identity and purity vary outside formal research. Its record separates the peptide sequence, a nominated bulk substance, a clinical-study product, and a consumer vial. The sequence is not in dispute; what is in the vial is. For TB-500, both questions remain open.
Approval and sport status
Neither molecule has an approved product or FDA-approved indication. The BPC-157 record describes its status as investigational with no approved formulation. The TB-500 record says that no FDA-approved TB-500 drug product exists.
Both appear in FDA compounding-review material. The BPC-157 record notes that FDA's July 2026 advisory-committee briefing evaluated BPC-157-related bulk substances for a nominated ulcerative-colitis use and documented evidence and safety gaps. An advisory-stage record supports scrutiny, but it is not a final FDA determination. Being reviewed is not the same as being rejected or approved.
On anti-doping the records converge. Both records carry a normalized status of Prohibited. BPC-157 is listed under WADA's S0 non-approved substances category and is prohibited at all times for covered athletes. TB-500 is named on the 2026 WADA Prohibited List as a prohibited thymosin-beta-4 derivative. The claim that athletes can use BPC-157 because it is not a steroid is graded Misleading, and the claim that TB-500 is allowed in tested sport is graded Misleading. The reasoning is the same in both cases: the prohibited list is not a list of steroids, and a substance's absence from any approval pathway is precisely what places it in category S0.
The site records this as a status, not as personal clearance. Athletes remain responsible for checking the current list, Global DRO, and their own governing body's rules.
What this page will not answer
Readers also ask for a protocol: which one, how much, whether to combine them, and for how long. This page does not provide that guidance.
The BPC-157 record excludes self-injection, reconstitution, dosing, sourcing, and stack instructions. “Research use only” does not establish quality or make a product appropriate for human use. The TB-500 record also excludes sourcing, reconstitution, injection, cycle, stack, and injury-treatment instructions.
There is a scientific reason too. A combination claim requires evidence about the combination, and neither record includes that evidence. Mentioning two molecules together does not create a supported claim.
What these records cannot answer
- The reviewed records contain no head-to-head comparison of BPC-157 and TB-500, and no study of the two used together.
- Neither record includes a human pharmacokinetic profile adequate for comparison. BPC-157's is described as sparse, and TB-500's is described in terms of fragment identity rather than clinical behaviour.
- No human outcome evidence for tendon, muscle, or wound healing is recorded for either molecule, so no healing-speed comparison is possible.
- The reviewed records include no comparative human safety dataset for either molecule; BPC-157's is described as too small for confident risk estimates and TB-500's as inadequate.
- FDA's compounding-review records for both substances are advisory-stage, and the reviewed records contain no final agency determination for either.
This page does not provide dosing, sourcing, or treatment advice.
Read the sources behind the comparison
BPC-157
TB-500